

Supplementary Table 5: Distribution of SGLT2i therapies at index date before and after propensity score matching in the SGLT2i 'clean' vs DPP-4i 'clean' cohorts.

At index date	Before matching		After matching	
	SGLT2i 'clean'	DPP-4i 'clean'	SGLT2i 'clean'	DPP-4i 'clean'
Total SGLT2i	27,980		18,583	
Dapagliflozin	10,029 (35.8%)		6,876 (37.0%)	
Empagliflozin	17,951 (64.2%)		11,707 (63.0%)	
Total DPP-4i		56,935		18,583
Alogliptin		530 (0.9%)		130 (0.7%)
Linagliptin		5,098 (9.0%)		1,462 (7.9%)
Saxagliptin		827 (1.5%)		207 (1.1%)
Sitagliptin		32,398 (56.9%)		11,072 (59.6%)
Vildagliptin		18,082 (31.8%)		5,712 (30.7%)

Please note that canagliflozin is not marketed in Hungary, and ertugliflozin was not yet available at the time of analysis.